Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/2/2020
SIETES contiene 92914 citas

 
 
<< anterior 21 a 40 de 20194 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction 2019;114:septiembre. [Ref.ID 103238]
22. Cita con resumen
Anónimo. FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. U.S. Food and Drug Administration 2019:13 de diciembre. [Ref.ID 103231]
23. Cita con resumen
Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R, Corne CE, Cooper AD, Criner GJ, Curtis JL, Han MK, Hatipoglu U, Helgeson ES, JAIN VV, Kalhan R, Kaminskiy D, Kaner R, Kunisaki KM, Lambert AA, Lammi MR, Lindberg S, Make BJ, Martinez FJ, McEvoy C, Panos RJ, Reed RM, Scanlon PD, Sciurba FC, Smith A, Sriram PS, Stringer WW, Weingarten JA, Wells JM, Westfall E, Lazarus SC, Connett JE, for the BLOCK COPD. Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med 2019;381:12 de diciembre. [Ref.ID 103230]
24.Enlace a cita original Cita con resumen
Garcez H, Fernandes C, Barbosa F, Pereira MR, Silveira C, Marques-Texeira J. Effects of benzodiazepines administration on identification of facial expressions of emotion: a meta-analysis. Psychopharmacology (Berl) 2019:noviermbre. [Ref.ID 103227]
25. Cita con resumen
Simó Miñana J. Guerras médicas: a propósito del ensayo EXCEL . Salud, dinero y atención primaria 2019:15 de diciembre. [Ref.ID 103225]
26. Cita con resumen
Parker L, Fabbri A, Grundy Q, Mintzes B, Bero L. “Asset exchange”—interactions between patient groups and pharmaceutical industry: Australian qualitative study. BMJ 2019;367:12 de diciembre. [Ref.ID 103224]
27. Cita con resumen
Blanco-Silvente L, Castells X, Garre-Olmo J, Vilalta-Franch J, Saez M, Barceló MA, Capellà D. Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer’s disease: a cumulative meta-analysis and trial sequential analysis. Eur J Clin Pharmacol 2019;75:diciembre. [Ref.ID 103212]
28. Cita con resumen
Shah R, Khan B, Latham SB, Khan SA, Rao SB. A meta-analysis of aspirin for the primary prevention of cardiovascular diseases in the context of contemporary preventive strategies. Am J Med 2019:31 de mayo. [Ref.ID 103205]
29. Cita con resumen
Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]
30. Cita con resumen
Hermida RC, Crespo JJ, Domínguez-Sardina M, et al.. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2019:septiembre. [Ref.ID 103201]
32.Enlace a cita original Cita con resumen
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereschchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M, for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:21 de noviembre. [Ref.ID 103194]
33. Cita con resumen
Anónimo. FDA approves first oral GLP-1 treatment for type 2 diabetes. FDA 2019:1. [Ref.ID 103193]
34.Enlace a cita original Cita con resumen
Waxmonsky JG, Pelham W 3rd, Campa A, Waschbusch DA, Li T, Marshall R, Babocsai L, Humphery H, Gnagy E, Swanson J, Hanc T, Fallahazad N, Pelham WE 4th. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. J Am Acad Child Adolesc Psychiatry 2019:29 de agosto. [Ref.ID 103191]
35.Enlace a cita original Cita con resumen
Cummings SR, Lui LY, Eastell R, Allen IE. Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern Med 2019:19 de agosto. [Ref.ID 103179]
36.Enlace a cita original Cita con resumen
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S, COMPASS Investigators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 2019;157:agosto. [Ref.ID 103177]
37.Enlace a cita original Cita con resumen
Hartholt KA, Lee R, Burns ER, van Beeck EF. Mortality from falls among US adults aged 75 years or older, 2000-2016. JAMA 2019;321:4 de junio. [Ref.ID 103174]
38. Cita con resumen
Young K. No evidence haloperidol helps in hospital delirium. Journal Watch 2019:3 de septiembre. [Ref.ID 103168]
39. Cita con resumen
van Eijk AM, Zulaika G, Lenchner M, Mason L, Sivakami M, Nyothach E, Unger H, Laserson KFPhillips-Howard PA. Menstrual cup use, leakage, acceptability, safety, and availability: a systematic review and meta-analysis. The Lancet Public Health 2019;4:1. [Ref.ID 103161]
40.Enlace a cita original Cita con resumen
Perkovic V, Jardine MJ, Neal BBompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, for the CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:13 de junio. [Ref.ID 103155]
Seleccionar todas
 
<< anterior 21 a 40 de 20194 siguiente >>